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Understanding luciferase enzymology and the structure of compounds that modulate luciferase activity can
be used to improve the design of luminescence-based assays. This review provides an overview of these
popular reporters with an emphasis on the commonly used firefly luciferase from Photinus pyralis (FLuc).
Large-scale chemical profile studies have identified a variety of scaffolds that inhibit FLuc. In some cell-
based assays, these inhibitors can act in a counterintuitive way, leading to a gain in luminescent signal.
Although formerly attributed to transcriptional activation, intracellular stabilization of FLuc is the primary
mechanism underlying this observation. FLuc inhibition and stabilization can be complex, as illustrated by
the compound PTC124, which is converted by FLuc in the presence of ATP to a high affinity multisubstrate
adduct inhibitor, PTC124-AMP. The potential influence these findings can have on drug discovery efforts is
provided here.Introduction
Technical advances in molecular biology, microtiter plate–based
spectrophotometry, and automation have enabled the develop-
ment of biologically relevant assays with robust performance
that can be utilized in high-throughput screening (HTS) for chem-
ical biology and drug discovery applications. These sophisti-
cated assays, characterized by their ability to be translated
from the bench to fully automated HTS systems while maintain-
ing sensitivity, signal strength, and biological fidelity, often
involve capturing a biological response using a single reporter
that has a light-based output. Although such assays greatly
improve our ability to monitor intricate biological processes,
incorporation of a biological reporter can influence assay results
in unintended and unanticipated ways. An understanding of
these reporter-related complexities is essential, and appropriate
follow-up assays should be aimed at identifying reporter-related
artifacts in order to validate the HTS result as well as provide an
accurate interpretation of structure activity relationships (SARs)
derived during subsequent probe/lead optimization efforts.
Bioluminescence is a commonly exploited detection tech-
nology used across academia and industry. An indicator of this
is evidenced by the nearly 2000 assays currently listed in the
PubChem database: approximately 21% are bioluminescence
and 53% are fluorescence, with the remainder using other assay
formats, such as absorbance (Figure 1) (see review by Inglese
et al., 2007, for an overview of different HTS assay formats).
Bioluminescent assays rely on luciferase enzymes, which cata-
lyze the oxidation of specific substrates known as luciferins
to form oxyluciferin, with the concurrent emission of a photon.
Although all luciferases catalyze light-emitting reactions, the
luciferin substrates are structurally diverse. Luciferases from
many bioluminescence-producing organisms have been cloned
and isolated for the purpose of constructing bioassay systems
(Fan and Wood, 2007; Hoshino, 2009), including luciferases
from fireflies (Lampyridae), click beetles (Elateridae), the larvae646 Chemistry & Biology 17, June 25, 2010 ª2010 Elsevier Ltd All rigof certain beetles known as glow worms (Phengodidae), and
various marine organisms such as the sea pansy (Renillidae).
This review provides a summary of commonly used luciferases
and suggests recommendations for their appropriate use in
common HTS assays. A particular focus is placed on the widely
used firefly luciferase, FLuc. All assay formats, including those
involving FLuc, have associated artifacts that interfere with the
interpretation of assay results. For this reason, we will describe
our efforts to apply titration-based screening (quantitative HTS
[qHTS]) to identify, categorize, and understand the behavior of
compounds that interact with FLuc in biochemical and cell-
based assays. Compounds that interfere with FLuc detection
are predominantly inhibitors of the enzyme but vary in their
mode of action, from simple competitive inhibitors to unique
multisubstrate adduct inhibitors, as illustrated by PTC124 (Atalu-
ren). Here we describe the complexities associated with reporter
enzymology and how this may influence compound discovery
efforts.
Overview of Luciferases and Uses in HTS
Luciferases used in HTS can be divided into several major
groups according to their substrate and cofactor dependence
and according to whether the enzyme is expressed intracellularly
or is secreted from cells (Table 1; see Table S1 available online).
Additionally, some luciferases are utilized for either cell- or
biochemical-based HTS assays, whereas others have been
developed for use in both assay formats (Table 1). One of the
main reasons for the widespread use of luciferase in bioassays
is that, unlike fluorescence, luminescence does not require exci-
tation light energy, thus lowering the background signal to
provide a sensitive assay with a high signal-to-background ratio.
Elimination of an excitation light source also prevents interfer-
ence by compound fluorescence (Simeonov et al., 2008) and
fluorophore photobleaching. Therefore, luminescence assays
can be very sensitive, despite a significantly weaker signalhts reserved
Figure 1. PubChem Analysis by Detection Type
Currently, of the >2000 assays listed in PubChem, bioluminescence and fluo-
rescence represent the two most prominent detection strategies. NCI is the
NCI-60 cell viability assay panel.
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FLuc or Renilla luciferase (RLuc) enzymes as reporters enables
the measurement of dynamic changes in reporter transcription
levels because the intracellular protein half-lives of these lucif-
erase enzymes are relatively short compared to nonenzymatic
fluorescent protein reporters such as GFP (protein half-life, 26
hr; Corish and Tyler-Smith, 1999). By comparison, the protein
half-lives of Gaussia luciferase (GLuc) (Wurdinger et al., 2008)
and Cypridina luciferin 2-monooxygenase (CLuc) (Nakajima
et al., 2004), once secreted, are significantly longer than those
of either FLuc or RLuc (6 days and 53 hr, respectively, in cell-
culture media; Table 1), although, at this time, neither GLuc nor
CLuc is commonly used in HTS.
The application of FLuc as a reporter began in the late 1980s,
following its initial cloning (de Wet et al., 1985), and expression in
mammalian cells (de Wet et al., 1985, 1987). The FLuc enzyme
was found to be a sensitive reporter for biological assays (de
Wet et al., 1987; Nguyen et al., 1988; Ow et al., 1986) and cata-
lytically active as a monomer (Wood, 1995) and was optimized
for expression and activity as a reporter gene in mammalian cells
(Wood, 1998), though it is now widely used for biochemical appli-
cations in HTS as well. A luciferase from a different species of
firefly, Photuris pennsylvanica, has also been optimized andTable 1. Luciferases Used in Chemical Biology Applications
Luciferase Species
Molecular
Weight
Peak Emission
Wavelength ATP
Firefly (FLuc) Photinus pyralis 62 kDa 550–570 nm Yes
Modified firefly
(Ultra-Glo)
Photuris
pennsylvanica
61 kDa 550–570 nm Yes
Click beetle
(CBLuc)
Pyrophorus
plagiophthalamus
60 kDa Green, 537 nm;
Red, 613 nm
Yes
Sea pansy (RLuc) Renilla reniformas 36 kDa 480 nm No
Copepod
crustacean
(GLuc)
Gaussia princeps 20 kDa 460 nm No
Ostracod
crustacean
(CLuc)
Cypridina
noctiluca
62 kDa 465 nm No
B, biochemical assay format; C, cell-based assay format; N/A, not applicab
a These luciferases are currently not widely used in HTS.
Chemistry & Bideveloped for use as a reporter (though for biochemical assays
only) on the basis of its utilization of D-luciferin (D-LH2) and
ATP as substrates (e.g., Ultra-Glo) (Fan and Wood, 2007).
Typical biochemical assays that utilize either FLuc or Ultra-Glo
include those that measure ATP or ADP concentrations (Singh
et al., 2004; Tanega et al., 2009) or use pro-luciferin substrates
to detect target protein activity (Cali et al., 2006; Fan and
Wood, 2007) (Table S1).
RLuc, another commonly used luciferase reporter (Roda et al.,
2009), does not share amino acid sequence similarity to FLuc
(Greer and Szalay, 2002; Lorenz et al., 1991) and light production
is ATP independent (Hart et al., 1979). RLuc is enzymatically
active as a monomer (Matthews et al., 1977), catalyzing the
oxidative decarboxylation of the luciferin coelenterazine via a
dioxetane intermediate prior to conversion to coelenteramide,
with the concurrent emission of blue light (Figure 2A) (Hart
et al., 1978). Compared with FLuc, RLuc has a few disadvan-
tages as an assay reporter, as described in Table S1.
The luciferases FLuc, RLuc, and the red- or green-emitting
Caribbean click beetle (CBLuc) varieties have been configured
for use in dual-luciferase assays. One such dual-luciferase assay
is designed such that activity from one luciferase (typically FLuc)
tracks with the target biology while the second luciferase (e.g.,
RLuc) is used for assay normalization (to account for cytotox-
icity, differences in cell number, and transfection efficiency in
the case of transiently transfected cell lines) (Stables et al.,
1999). In this dual-luciferase assay system, measurement of
the two luciferases is sequential, requiring separate substrate
addition steps (Figure 2A), because the two luciferases need
different substrates and collection of the second luminescence
signal requires termination of the preceding reaction (Hannah
et al., 1998). Commercial detection reagents are available for
sequential measurement of FLuc and RLuc, but noncommercial
formulations have also been described (Dyer et al., 2000).
Although the FLuc/RLuc dual-luciferase assay is ratiometric by
design, limitations to this system should be considered. For mini-
aturized assay volumes (<10 mL), the two-step addition protocol
is not optimal because of well volume limitations. Additionally, as
discussed in detail in the following section, either luciferase
enzyme can be inhibited by small molecule compounds used-Dependent? Substrates Secreted?
Protein
half-life
HTS Assay
Type
D-luciferin/ATP No 3 hr B & C
D-luciferin/ATP No N/A B
D-luciferin/ATP No 7 hr C
Coelenterazine No 4.5 hr B & C
Coelenterazine Yes 6 days
(in cell
media)
—a
Vargulin (aka
Cypridina
luciferin)
Yes 53 hr
(in cell
media)
— a
le. The luciferase is not currently used in cell-based formats.
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Figure 2. Luciferase Assay Configurations
(A) The dual luciferase assay protocol is illustrated.
Cells are lysed with a detection reagent containing
luciferase substrates (1), FLuc luminescence is
measured (2), the FLuc reaction is then stopped
along with the addition of the coelenterazine
substrate for RLuc (3), and luminescence is again
measured (4). In this case, total luminescence is
measured using a clear filter; the luminescence
emission spectra of FLuc and RLuc are also
shown (CPS, counts per second measured on
a luminometer).
(B) CBLuc two-color dual-luciferase assay
protocol is shown in which cell lysis and detection
are performed with a single reagent addition (1)
and green luminescence and red luminescence
are then measured sequentially on a microtiter
plate reader (2) using the appropriate optical
filters. The luminescence emission maximums
are noted, and the luminescence emission spectra
for both green and red CBLuc are shown below.
The dotted lines on the emission spectra represent
the optical filters used in (Davis et al., 2007).
(C) A live cell kinetic assay is depicted using
a secreted luciferase (GLuc) that uses coelentera-
zine as the substrate. Cell culture supernatant
containing the secreted GLuc is removed at
different times (1) and upon mixing with the coe-
lenterazine substrate (2) the total luminescence
for each time point is measured using a clear filter
(3, 4, 5...). Also shown is the emission spectra for
GLuc relative to RLuc (spectra adapted from Tan-
nous et al., 2005). The GLuc wavelength emission
maximum is similar to RLuc, but GLuc shows
brighter luminescence.
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RLuc, which are evolutionarily unrelated and have different
substrate specificities (Loening et al., 2007), it is expected that
these two enzymes will have dissimilar inhibition profiles. Thus,
the changes in the FLuc/RLuc luminescence ratio intended to
be reflective of target modulation could actually be the result of
the direct and selective inhibition of either luciferase reporter
enzyme.
An alternative dual-luciferase reporter-gene assay takes
advantage of luciferase mutants derived from the yellow-light-
emitting CBLuc. Variants of CBLuc, which share over 95%
amino acid identity and catalyze the oxidation of the same
substrate, D-LH2, have been engineered to emit either green or
red light (Almond et al., 2003; Wood et al., 1989). The two-color
dual-luciferase assay requires a single substrate addition with
activity from the two variant luciferases differentiated according
to their shifted bioluminescent emission wavelengths (Figure 2B).648 Chemistry & Biology 17, June 25, 2010 ª2010 Elsevier Ltd All rights reservedBecause of high amino acid sequence
similarity, it is expected that inhibitors
would most likely affect both CBLucs
similarly—that is, a chemical that in-
hibited the enzymatic activity of one
CBLuc would inhibit the other as well,
thus giving an advantage to the two-color
dual-luciferase assay over the FLuc/RLuc
dual-luciferase assay. One disadvantage
of the CBLuc assay is the, albeit partial,
spectral overlap of light emitted by theseluciferases. This necessitates the calculation of correction
factors for the overlapping green and red emission spectra using
separate cell lines that express the individual CBLuc variants
(Davis et al., 2007).
Detection of the beetle luciferases (FLuc and CBLuc) in cell-
based reporter gene assays used in HTS typically requires cell
lysis, and as such, restricts these assays to a single end point
measurement of luciferase activity. The use of luciferases that
are naturally secreted, such as GLuc (Verhaegent and Christo-
poulos, 2002) or CLuc (Nakajima et al., 2004), appear to be
suited for assays that could benefit from noninvasive detection
of reporter response at different time points throughout the
course of an experiment (Figure 2C). GLuc is monomeric, repre-
sents the smallest luciferase cloned to date (at 20 kDa), and
contains a signal sequence required for efficient expression,
secretion, and activity of the enzyme (Tannous et al., 2005).
Although GLuc produces brighter luminescence than RLuc, it
Figure 3. Bioluminescent and Dark Reactions Catalyzed by FLuc
(A) The light reaction catalyzed by FLuc (i). The substrates D-luciferin (D-LH2) and ATP are used by FLuc to form a luciferyl-adenylate intermediate (LH2-AMP). This
intermediate then undergoes nucleophilic attack by molecular oxygen, and upon subsequent displacement of AMP, an unstable dioxetanone is formed, which
then spontaneously breaks down to form oxylucifein, and CO2 with the emission of a photon (Marques and Esteves da Silva, 2009). (ii) Dark reactions catalyzed by
FLuc are shown in the gray shaded area. One of these involves a side-reaction in which oxidation of LH2-AMP occurs to form the potent inhibitor L-AMP, which
can undergo pyrophosphorolysis or thiolysis to yield less potent inhibitors, L or L-CoA, respectively (Fontes et al., 1997).
(B) FLuc has also been reported to use certain fatty acids as substrates yielding fatty acyl-CoA metabolites. Kinetic constants for the synthesis of lineoic acid-CoA
are taken from Oba et al. (2003).
(C) The potent inhibition observed for the novel 3,5-diaryloxadiazole, PTC124, is due to exploitation of a dark reaction catalyzed by FLuc in which PTC124 forms
an adduct with AMP via its m-carboxylate. Also shown is the potential FLuc-catalyzed thiolysis of PTC124-AMP by CoASH to yield a metabolite, PTC124-CoA.
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readers (Tannous et al., 2005). To address this, GLuc variants
have been constructed whose luminescence half-life is stable
over several minutes, although the specific activity of these vari-
ants is significantly less. However, stable light emission appears
achievable by adding 0.1% Triton to the supernatant obtained
from GLuc-secreting cells (Maguire et al., 2009).
Structure and Function of FLuc
FLuc is a member of a superfamily of adenylate-forming
enzymes, which includes acyl- and aryl-CoA synthetases, and
nonribosomal peptide synthetases (Gulick, 2009) and by primary
sequence homology, appears to be most closely related to
certain acyl-CoA ligases (30% homology to plant 4-coumara-
te:CoA ligase) (Baldwin, 1996). Transfer of an adenylate group
to a substrate to form an enzyme-associated intermediate is,
mechanistically, a common mode of substrate activation in this
enzyme family (Conti et al., 1996; McElroy et al., 1967).
FLuc is an ATP-hydrolyzing, decarboxylating 4-oxidoreduc-
tase that requires a luciferin substrate containing a hydroxy-ben-Chemistry & Bizothiazolyl-thiazoline-carboxylic acid structure (D-LH2), ATP,
oxygen, and a metal cation (typically Mg2+) to produce light
(Figure 3Ai) (Marques and Esteves da Silva, 2009). Biolumines-
cence is produced from D-LH2 by FLuc through an SN2
nucleophilic displacement reaction in which the carboxylate
on the thiazoline ring attacks the a-phosphoryl moiety of ATP
(Figure 3Ai). The first step in the reaction results in the release
of PPi and the formation of an enzyme-bound luciferyl-adenylate,
LH2-AMP (Fraga et al., 2004; Rhodes and McElroy, 1958).
The second step of the reaction involves the oxidation of
LH2-AMP by molecular oxygen. This leads to the production of
an unstable luciferin dioxetanone, which generates CO2 and an
electronically excited oxyluciferin which, upon spontaneous
decay to the ground state, generates photons of both green
and red light (Figure 3Ai) (Inouye, 2010; Marques and Esteves
da Silva, 2009).
In addition to catalyzing a light-emitting reaction, several side-
reactions that do not produce light, so-called ‘‘dark’’ reactions,
are also catalyzed by FLuc. One such dark reaction involves
the oxidation of LH2-AMP resulting in the formation ofology 17, June 25, 2010 ª2010 Elsevier Ltd All rights reserved 649
Figure 4. Structure of Beetle Luciferases
(A) The apo structure of FLuc as determined by
Conti et al. (1996) is shown (PDB: 1LCI) depicting
the secondary a and b structural elements
comprising the N- and C-terminal domains.
(B) Overlay of the apo FLuc structure (cyan) with
the DLSA-bound structure of LcrLuc (gold; PDB
2D1S). Closure of the cleft between the N- and
C-terminal domains is observed in the DLSA-
bound structure. The active site resides in the
N-terminal domain near the cleft.
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e 3Aii). L-AMP has been shown to be a tight-binding active site
inhibitor (Rhodes and McElroy, 1958; Ribeiro and Esteves da
Silva, 2008) (Figure 3Aii), and it has been documented that up
to 20% of the D-LH2 substrate is diverted to formation of this
inhibitory compound (Fraga et al., 2006). The L-AMP inhibitor
is an example of a special type of enzyme inhibition in which
the enzyme catalyzes the formation of its own inhibitor. This
type of inhibitor is known as a multisubstrate adduct inhibitor
(MAI), the affinity of which can be estimated from the product
of the KDs for the two substrates (D-LH2 and ATP) and in the
case of L-AMP, nanomolar inhibition is observed (Figure 3Aii).
Interestingly, the flashing of fireflies as seen on a summer’s night
may be attributed to the light-producing luciferase reaction inter-
rupted intermittently by rapid and potent inhibition of the biolumi-
nescent reaction through formation of L-AMP (Ghiradella and
Schmidt, 2004). Regeneration of active luciferase within the
firefly lantern is believed to occur either by reaction of L-AMP
with pyrophosphate and/or CoASH, as breakdown of L-AMP
has been observed when micromolar concentrations of these
compounds are added to in vitro FLuc reactions (Fontes et al.,
2008; Fraga et al., 2005) (Figure 3Aii). Both pyrophosphorolysis
and thiolysis of L-AMP yield less potent (mM) inhibitors (L or
L-CoA, respectively), thus facilitating competition by the D-LH2
substrate and regeneration of the active enzyme (Marques and
Esteves da Silva, 2009). Commercial FLuc detection reagents
often contain CoASH, and addition of 100 mM CoASH to the
FLuc reaction converts the bioluminescence from a flash to
a glow response (Fraga et al., 2005).
FLuc catalysis utilizing CoASH as a substrate (Fraga et al.,
2005) is not surprising considering that FLuc and fatty acyl-
CoA synthetases belong to the same superfamily (Gulick,
2009; Oba et al., 2003). Indeed, FLuc can catalyze the formation
of certain fatty acyl-CoAs (>C16; Figure 3B) from substrates such
as arachidonic acid, albeit at a reduced catalytic efficiency rela-
tive to the luciferin reaction (Oba et al., 2003). Additionally, Oba650 Chemistry & Biology 17, June 25, 2010 ª2010 Elsevier Ltd All rights reservedand colleagues (2009) have been able to
convert a fatty acyl-CoA synthetase
derived from a nonluminous click beetle
into a luciferase enzyme through point
mutations of active site residues (Oba
et al., 2009). These studies lend support
to the premise that FLuc arose from an
ancestral fatty acyl-CoA synthetase.
FLuc was the first enzyme in the super-
family of adenylate-forming enzymes
for which the X-ray structure wasdetermined (Conti et al., 1996). The apo FLuc structure consists
of N-terminal and C-terminal domains, both containing a+b
structure, that are linked by a flexible hinge region (Figure 4A)
(Conti et al., 1996). The active site of the enzyme is located in
the N-terminal domain near the hinge region (Conti et al.,
1996). In addition, it was noted by Conti et al. (1996) that the
structure of FLuc has a novel ATP-binding motif (PDB:1LCI).
One of the most informative structures for examining the
role of active site residues is the 1.3 A˚ resolution co-crystal
structure for the firefly luciferase from Luciola cruciata (LcrLuc)
bound to an analog of the luciferyl-adenylate intermediate
(50-O-[dehydroluciferyl)-sulfamoyl]adenosine; DLSA; PDB: 2D1S)
(Nakatsu et al., 2006). The structure of the DLSA-bound to beetle
luciferase confirms the role of many of the invariant residues in
FLuc (identified by Conti et al., 1996) that are involved with
substrate binding, for example, Asp424 of LcrLuc forms H-bonds
to the ribose ring of ATP (Figure 5A). Also found at the active site
of LcrLuc is a nine-residue peptide containing a signature
sequence for this enzyme superfamily, with invariant residues
Gly202 and Lys208 anchoring the ends of this peptide. A third
motif is found to line the active site and contains the invariant
residue Glu346 of LcrLuc. This structure confirms that the enzyme
active site is lined by three regions originally identified by Conti
et al. (1996).
Comparison of the apo FLuc (Conti et al., 1996) and LcrLuc:
DLSA-bound (Nakatsu et al., 2006) structures suggest that a
conformational change occurs upon substrate binding, wherein
a large cleft between the N- and C-terminal domains closes (Fig-
ure 4B). Closure of this cleft is thought to increase catalytic effi-
ciency, perhaps by waterexclusion, which would prevent quench-
ing of the excited oxyluciferin product (Conti et al., 1996; Nakatsu
et al., 2006). Recently, robust biosensors for HTS assays have
been developed using an approach that takes advantage of
this conformational change—circularly permuted reporters (Fan
et al., 2008). These reporters have been used in assays to detect
cAMP(and other cellularanalytes), as well as intracellularprotease
A B
D424
G202
K208
E346
D424
G202
K208
E346
Figure 5. Inhibitor-Bound Beetle Luciferase
Structures
(A) The LcrLuc:DLSA-bound structure is shown
and the three conserved motifs, originally
proposed by Conti et al. (1996) as likely candidates
of the active site are shown in cyan. Several
invariant residues that line the active site are high-
lighted (residue numbering based on LcrLuc).
(B) Overlay of the LcrLuc:DLSA-bound structure to
the FLuc:PTC124-AMP bound inhibitor complex.
LcrLuc:DLSA (protein in gold; ligand in green),
PTC124-AMP (protein in purple; ligand in yellow).
Conserved motifs are again shown in cyan. The
interactions and conformations of both ligands
and invariant protein regions are highly conserved
between the two structures.
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sensors) (Table S1) (Binkowski et al., 2009; Fan et al., 2008).
Defining FLuc Inhibitor Chemotypes Using Quantitative
HTS (qHTS)
To better understand the nature and frequency of FLuc inhibition
by small molecules, we have profiled a 72 K portion of the Molec-
ular Libraries Small Molecule Repository (MLSMR; PubChem
Assay Identification [AID] 411) for FLuc activity (in an assay using
a commercial detection reagent formulated to measure ATP
levels; Auld et al., 2008a). Through screening at multiple
compound concentrations (qHTS) (Inglese et al., 2006), potency
and efficacy values were derived for every compound in this
representative library. From the FLuc qHTS, we found that
approximately 3% of the compounds in this screen inhibited
FLuc. Potent inhibition (IC50 % 10 mM), well within typical
screening concentration ranges, was observed for 0.9% of the
library. Major chemical series associated with FLuc inhibition
included mimics of the D-LH2 substrate, such as benzthiazoles,
benzimidazoles, and benzoxazoles, as well as chemical series
that are devoid of obvious structural similarity to either ATP or
D-LH2 substrates, such as the 3,5-diaryl oxadiazoles (Figure 6A).
Additional experiments confirmed that many of the benzthiazole-
type compounds were competitive with D-LH2 (see Figure 6B
for example).
This profiling work also highlighted two key variables to
consider when examining library activity against FLuc—the
source of luciferase and the formulation of substrate reagents
used (KM concentrations of substrates versus excess substrates
typical of detection reagents). For example, the widely used
luciferase-based detection reagents (Cell TiterGlo or biochem-
ical assay formats based on pro-luciferin substrates, such as
P450 Glo) from Promega Corporation contain theP.pennsylvanica
luciferase variant Ultra-Glo. Our profiling work indicates that
Ultra-Glo is less likely to be inhibited by compounds used in
screening (Auld et al., 2009b). Additionally, although many of
the same chemotypes were found to inhibit both luciferases,
these compounds were significantly less potent against a formu-
lation of Ultra-Glo (PubChem AID: 1379; Figure 6C). An example
of this is illustrated by the activity of a series of quinoline
compounds, which demonstrated inhibition in the FLuc qHTS
but were only weakly active against purified Ultra-Glo luciferase
(Figure 6D). The quinoline/quinazoline scaffold is also found
among known ATP-competitive protein kinase inhibitors. How-
ever, consistent with the unique ATP-binding fold characteristicChemistry & Biof FLuc, these specific compounds have not been found to
inhibit protein kinases (Auld et al., 2008a). Interestingly, a qHTS
assay for the protein kinase Clk4 constructed to detect ATP
depletion or ADP production performed against a kinase-
focused (quinazoline/pyrimidine) compound library using a for-
mulation of Ultra-Glo showed potent inhibition of Clk4, but no
inhibitors were identified for luciferase (PubChem AID: 1379)
(Tanega et al., 2009).
Another important consideration when performing a counter-
screen/profile for compounds that may inhibit FLuc is detection
reagent formulation. If one wants to identify even weakly com-
petitive inhibitors, it is necessary to determine the activity of
FLuc in the presence of KM concentrations of substrates. Profiling
FLuc activity in the presence of detection reagents, which contain
excess FLuc substrates (in addition to coenzyme CoASH), may
not identify weakly competitive inhibitors. However, if one is
concerned only with identifying false positives (FLuc inhibitors)
in the specific assay, detection reagents identical to those utilized
in the assay can be used, as long as the FLuc enzyme concentra-
tion in the assays is very similar. Additionally, diluting commer-
cially available FLuc detection reagents to save cost can result
in detecting more FLuc inhibitors (relative to undiluted detection
reagents), as the concentration of FLuc substrates is less, thus
allowing inhibition by less potent FLuc inhibitors.
Effects of Luciferase Inhibitors in Cell-Based Assays
Activity of FLuc in cell-based assays can be confounded by
compounds that inhibit the FLuc enzyme, causing apparent inhi-
bition (Bakhtiarova et al., 2006), or counter to one’s intuition, an
increase of luminescence. It has been found that the FLuc
protein is sensitive to the phenomenon of ligand-based stabiliza-
tion by inhibitory compounds, leading to protein stabilization and
accumulation of the affected protein (Thompson et al., 1991).
This phenomenon has been observed for many proteins and
has recently been described as a method to identify protein
targets of compounds (Lomenick et al., 2009). Thompson et al.
(1991) were the first to note that treatment of FLuc-expressing
mammalian cells with simple benzthiazole inhibitors led to
increased reporter protein levels in a transcriptional- and
translational-independent manner, resulting in a counterintuitive
increase in luciferase signal upon detection.
As it turns out, intracellular stabilization of FLuc by inhibitory
compounds is both a general and prevalent phenomena in
cell-based assays. Using the SAR derived from the FLuc profile
of the MLSMR described above, we performed a retrospectiveology 17, June 25, 2010 ª2010 Elsevier Ltd All rights reserved 651
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Figure 6. Types and Behavior of Firefly Luciferase Inhibitors
(A) Potency distribution (pAC50) for four prominent chemotypes found to inhibit FLuc from profiling efforts. Shown are benzthiazoles (i), benzimidazoles (ii), ben-
zoxazoles (iii), and 3,5-diaryl-oxadiazoles (iv).
(B) Comparison of FLuc and Ultra-Glo luciferase against a 2-phenylbenzothiazole luciferase inhibitor at multiple substrate concentrations. Graphs of ATP vari-
ation (main) or D-LH2 variation (inset) are shown and were varied at 0.25, 2, 25, and 250 mM, resulting in four sets of CRCs. In each case, the constant substrate
was present at 250 mM. The FLuc data are shown as solid circles, and the Ultra-Glo luciferase data are shown as open circles. Simple benzthiazoles appear to be
purely competitive with D-LH2 for either luciferase as seen from the right shift of the CRCs (decrease in potency).
(C) Difference in potency distribution between inhibitors identified in a commercial formulation of FLuc (PK-Light) and a commercial formulation of Ultra-Glo
(KinaseGlo), illustrating how the source of luciferase reagent can affect in vitro assay interference.
(D) Comparison of FLuc and Ultra-Glo luciferase inhibition potencies for quinoline analogs assayed using KM levels of substrates. CRCs for quinolines
i (squares) and ii (circles) are shown for FLuc (solid shapes and dotted lines) and Ultra-Glo luciferase (open shapes and solid lines). Selectivity between
the two luciferases is observed for such quinolines. Figures adapted from Auld et al. (2008a, 2009b). The error bars correspond to the standard deviation
of the mean.
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based assays that used FLuc as the reporter (Auld et al.,
2008b). As expected, we found an enrichment of FLuc inhibitors
among compounds that scored positive in cell-based assays
aimed at measuring a decrease in FLuc activity (38% ± 8% of
the positives were FLuc inhibitors). However, we also found
a significant enrichment of FLuc inhibitors in cell-based assays
designed to measure an increase in FLuc activity (46% ± 10%
of the positives were FLuc inhibitors), a result indicative of the
apparent signal activation characteristic of inhibitor-based stabi-
lization of FLuc. Inhibitor-based stabilization was found to occur
for all the major chemotypes identified in the original profile study
(Figure 6A). This finding supported previous work, which indi-
cated that intracellular FLuc inhibition can lead to an apparent
activation response in cell-based assays—a counterintuitive
result for an enzyme inhibitor—which can confound the identifi-
cation of compounds with target activity.
It is not always obvious, in cell-based assays, to identify
compounds that cause FLuc inhibitor-based stabilization. This
is because the type of inhibition (reversible, irreversible,652 Chemistry & Biology 17, June 25, 2010 ª2010 Elsevier Ltd All rigcompetitive or noncompetitive), affinity of the inhibitor for
FLuc, basal luciferase expression, and assay format and
protocol all influence whether the compound appears to cause
an increase or decrease in FLuc activity at the compound con-
centration tested. Additionally, concentration response curves
(CRCs) generated for these compounds in the cell-based FLuc
assay can be sigmoidal or bell-shaped (Figure 7A) (Auld et al.,
2008a; Inglese et al., 2009; Peltz et al., 2009). Upon incubation
of compound with cells, a stable E,I complex is formed that
prevents or slows FLuc enzyme degradation, thus allowing
enzyme levels to increase in cell culture over time relative to
controls not treated with inhibitor compound. Furthermore, the
concentration of E will be modulated by the affinity of the inhib-
itor (KI) for the free enzyme. When the ratio of inhibitor to KI is
high, the slower degrading E,I complex is maximized and
degradation is minimized. This model predicts that, at different
concentrations of I, the amount of active enzyme will follow
a CRC with an apparent EC50 centered on the KI value (Fig-
ure 7A). However, detection of FLuc activity is possible for cells
treated with competitive FLuc inhibitors because thesehts reserved
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Figure 7. Posttranslational Inhibitor-Based Reporter-Stabilization
(A) Level of apparent reporter activation depends on properties of the luciferase inhibitor and the assay detection protocol used. Shown is the theoretically
observed activity of the reporter enzyme in the presence of a FLuc inhibitor, as determined in a biochemical assay in which substrate concentrations are held
near their KM values (orange line). Inset graph, the theoretical increase in enzyme concentration in the cell-based assay occurring as a result of inhibitor-based
stabilization. Theoretical reporter activity in the cell-based assay for a fully reversible FLuc inhibitor is shown (blue line). In this case, the addition of excess beetle
luciferase substrates in detection reagents fully relieves inhibition by the competitive inhibitor, causing apparent activation of FLuc that shows compound concen-
tration dependence. This type of CRC can also result when a reversible inhibitor is removed by washing cells prior to detection. The theoretical activity for an
irreversible FLuc inhibitor is shown for both a biochemical and cell-based assay (red line). Here, only inhibition of the reporter activity is observed in the cell-based
assay.
(B) Observed effect for a FLuc inhibitor (PTC124) using a no-wash protocol and Steady-Glo detection reagent (Promega). The top graph shows FLuc activity
obtained from HEK293 cells transfected with the construct pGL3 (Promega; E1741) after treatment with PTC124 for 72 hr (orange). The pGL3 construct contains
fluc under the control of a SV40 promoter. A bell-shaped CRC is observed in the cell-based assay resulting from the persistent inhibition of FLuc at high concen-
trations of compound. Also shown is the activity of PTC124 against purified FLuc assayed using KM levels of substrate (black data; bottom graph). Data are from
Auld et al. (2009a).
(C) Experimental results for the three regioisomers shown at right, for the FLucUGA cell-based assay (top) and the enzyme assay at KM levels of substrate (bottom).
Data are from Auld et al. (2010). Apparent activation in the cell-based assay and potency in the biochemical assay correlate with the reactivity of the carboxylate
regioisomers for MAI formation (colors correspond to the structures shown). The error bars correspond to the standard deviation of the mean.
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reagents that contain high concentrations of FLuc substrates
(ATP, D-LH2, and CoASH). When these inhibitors are competed
off FLuc by excess substrates, the enzyme is able to catalyze
the luminescence reaction, resulting in an apparent increase in
assay signal, due to the accumulated FLuc. To reiterate, in the
case of inhibitor-based stabilization, a competitive FLuc inhib-
itor will cause an apparent decrease in reporter activity when
substrate levels are less than or equal to KM (because FLuc
remains inhibited); however, when substrate levels are high
enough to compete with the inhibitory compound (as is the
case for detection reagents), an increase in reporter activity is
detected. Experimentally, a concentration-dependent com-
posite of FLuc activation due to stabilization at midlevel concen-
trations of compound followed by inhibition of FLuc activity at
higher inhibitor concentrations, leading to bell-shaped CRCs,
is observed (Figure 7B). In some cases, the inhibitory com-
pounds may be noncompetitive with FLuc substrates—for
example, covalent irreversible inactivation, or possibly inhibitors
that destabilize the FLuc enzyme intracellularly—which would
lead to an apparent inhibitory response upon detection
(Figure 7A).
Inhibition of enzymatic reporters is not limited to FLuc, and
RLuc inhibitors have also been identified. In fact, the well-
used tool compound H-89, used to modulate the protein kinase
PKA (Herbst et al., 2009), inhibits RLuc. In addition, posttransla-
tional ligand-based reporter stabilization has also been ob-
served for RLuc (Auld et al., 2009a). Although RLuc has not
been broadly profiled against a large chemical library, a pilot
screen of a library available from Tocris Inc. indicated that
approximately 10% of the library inhibited RLuc (in an assayChemistry & Biusing KM levels of coelenterazine; unpublished observation).
Thus, it seems that profiling for RLuc inhibitors in small molecule
libraries would prove informative and useful.
Role of Dark Reactions in the Formation of Novel Potent
Inhibitors
One of the most potent synthetic FLuc inhibitors identified to
date is PTC124 (Ataluren), a compound derived from a series
of FLuc assays aimed at identifying nonsense codon suppres-
sion agents (Welch et al., 2007). PTC124 possesses a 3,5-diaryl
oxadiazole scaffold, one of the prominent inhibitor scaffolds
identified in the FLuc profile of the MLSMR chemical library
(Figure 6Aiv). To examine whether inhibitor-based reporter stabi-
lization could explain the apparent activation of cellular FLuc
activity by PTC124, we constructed the primary cell-based
assay used to discover PTC124 -the FLucUGA assay in which
cells are either stably or transiently transfected with a construct
that contains the fluc cDNA with a UGA stop codon. Compounds
that appear to increase FLuc activity, presumably as a result of
enhanced readthrough of the premature UGA stop codon and
production of functional FLuc protein, are considered active in
the assay. We were able to reproduce the apparent activation
by PTC124 and related analogs in this cell-based assay. We
also found that this assay was highly sensitive to FLuc stabiliza-
tion by inhibitor compounds, as extremely low, but detectable,
levels of nonspecific readthrough of the flucUGA gene provided
a pool of FLuc protein with which compound could associate,
eventually leading to accumulation of FLuc protein inside the
cell (Auld et al., 2009a; Peltz et al., 2009). We also observed
that activation in the cell-based FLucUGA assay mirrored the inhi-
bition by the compounds against the purified FLuc enzyme,ology 17, June 25, 2010 ª2010 Elsevier Ltd All rights reserved 653
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assay was due to formation of a stable cellular E,I complex.
Additionally, we found that PTC124 was not active in an analo-
gous RLuc UGA cell-based assay. Correspondingly, RLuc enzy-
matic activity was found to be refractory to inhibition by
PTC124 and other structurally related diaryl-oxadiazole analogs,
demonstrating that PTC124 activation in the FLucUGA cell-based
assay was reporter specific and independent of transcriptional
or translational mechanisms. This study demonstrated that the
discovery of PTC124 was highly biased by the FLuc reporter
(Auld et al., 2009a).
The X-ray crystal structure of the E,I complex was determined
in an effort to understand the structural basis for high-affinity
binding and stabilization of FLuc by PTC124 (Auld et al., 2010).
Remarkably, when FLuc was crystallized in the presence of
both PTC124 and ATP, a PTC124-AMP adduct was revealed in
the active site of FLuc (Auld et al., 2010). Subsequent experi-
ments confirmed that FLuc catalyzes the formation of this
adenylate with PTC124 through nucleophilic displacement of
the pyrophosphate from ATP by the m-carboxylate of PTC124
(Auld et al., 2010). In addition, PTC124-AMP was found to bind
with high affinity to FLuc, with a KD 120 pM (Auld et al., 2010)
(Figure 3C).
The formation of PTC124-AMP by FLuc exemplifies a dark
reaction catalyzed by FLuc analogous to the naturally occurring
side-reaction that results in L-AMP formation from LH2-AMP
formation (see section above and Figures 3Aii and 3C). In fact,
it appears that PTC124-AMP represents a structural mimic of
the LH2-AMP intermediate. Indeed, overlay of the FLuc:PTC-
AMP structure with the LcrLuc:DLSA structure indicated
essentially identical binding modes and conformations of critical
invariant residues in the FLuc/LcrLuc active sites with the
respective MAI bound (Figure 5B) (Auld et al., 2010). Further-
more, the precise positioning of the PTC124 carboxylate in
the active site of the enzyme is required for efficient enzymatic
formation of the MAI, which would explain why simple aromatic
acids have not been observed as FLuc inhibitors. The m-carbox-
ylate of PTC124 is optimal for formation of the MAI, as demon-
strated by the reduced or eliminated ability of para- or ortho-
carboxylate analogs of PTC124, respectively, to form MAIs.
We reasoned that this is due to kinetic and energetic barriers
that impair the formation of the proper near-attack conformers
(NACs) required for the nucleophilic displacement reaction.
Our studies indicate that the o-carboxylate cannot achieve the
required NAC, because this would require rotation of the rigid
oxadiazole core outside the luciferin pocket, and that MAI forma-
tion by the p-carboxylate analog is kinetically unfavorable (Auld
et al., 2010).
Not surprisingly, formation of the PTC124-AMP MAI correlated
with stabilization of the FLuc protein. Testing PTC124 and
analogs, in addition to the PTC124-AMP adduct, in a thermal
denaturation assay, showed PTC124-AMP to produce the
greatest change in TM (DTM 30C), and that thermal stabiliza-
tion of FLuc correlated with the ability the PTC124 carboxylate
regioisomers to form the MAI (Auld et al., 2010). In addition, we
found that the potency in both the purified FLuc enzyme assay
and FLucUGA assay correlated with MAI formation, following
the reactivity of the carboxylate with meta > para > > ortho
(Figure 7C; see also Auld et al., 2010).654 Chemistry & Biology 17, June 25, 2010 ª2010 Elsevier Ltd All rigAlthough these findings describe how the FLuc reporter cata-
lyzes the production of a potent, stabilizing MAI (PTC124-AMP),
less clear is how FLuc activity could be measured during the
detection step of a cell-based FLuc reporter gene assay in the
presence of this potent inhibitor. On the contrary, a decrease
in luminescence would be expected because of the extremely
high affinity of PTC124 for FLuc. Apparent activation of FLuc in
cell-based assays upon PTC124 treatment can be explained
by the presence of CoASH in detection reagents. As mentioned
previously, FLuc catalyzes thiolysis of the potent L-AMP inhibitor
with CoASH (Figure 3Aii). We also found that the potency of
PTC124 is reduced by approximately 35-fold in the presence
of 500 mM CoASH, a concentration likely present in luciferase
detection reagents. Formation of PTC124-CoA through a simi-
larly FLuc-catalyzed thiolysis reaction would thus explain why
PTC124 appears to increase, as oppose to inhibit, FLuc activity
in an end-point assay: PTC124-CoA (Figure 3C), which is
expected to be a less potent inhibitor, could more readily disso-
ciate and be competed off of the enzyme by excess D-LH2
present in detection reagents.
It is routinely observed that the potency of a compound against
its molecular target appears weaker in cellular settings because
of the presence of competitive cofactors or substrates. In this
case, intracellular reactivity or competition of the MAI by free
CoASH or ATP, respectively, could explain why PTC124 potency
is nanomolar instead of picomolar in the cell-based assay. Thus,
although activation in the cell-based FLucUGA assay has been
used to suggest that PTC124 is a potent nonsense codon
suppression agent (Peltz et al., 2009; Welch et al., 2007), a biolog-
ically plausible mechanism for these results is that FLuc is the
molecular target of PTC124 in FLuc-cell-based assays.
Interpretation of FLuc Assay Results
The manifestation of the interaction of PTC124 with the FLuc
reporter in biochemical and cell-based assays—as an inhibitor
or activator of FLuc depending on the assay format—illustrates
how manipulation of biology to accommodate a reporter output
can introduce unexpected new complexities. For compounds
identified as active in FLuc assays, it is essential to determine
whether the compound has activity attributable to a direct inter-
action with FLuc. A simple way to do this is to measure the
potency of the compound(s) against purified FLuc using KM
concentrations of substrates. In addition, PubChem is a publicly
available resource that contains HTS data from many different
types of assays and can be used to determine whether certain
structural classes of compounds display activity in other FLuc
assays. Although these datasets have been useful for defining
common FLuc inhibitor chemotypes, it should be noted that
they are not the optimal counter-screen for cell-based assay
results. This is because the majority of these data is based on
assay formats that involve FLuc detection reagents, which often
contain excess substrates, which may mask the inhibitory
activity of substrate-competitive inhibitors. This is a particularly
important consideration because not all competitive inhibitors
of FLuc are obviously structurally related to the D-LH2 substrate,
a good example being the 3,5-diaryloxadiazoles. To have greater
certainty that a given compound does not inhibit FLuc, we
recommend an enzyme assay conducted with KM levels of
ATP and D-LH2 substrates (Auld et al., 2009a; Auld et al.,hts reserved
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the KI (Cheng and Prusoff, 1973).
Ideally, it is always preferable to pursue compounds from FLuc
reporter assays that have no activity against FLuc. However,
if it is necessary to pursue compound(s) that potentially have
dual activity—that is, activity against FLuc and the target of
interest—a rigorous orthogonal assay should always be per-
formed to confirm activity at the desired target. An orthogonal
assay is directed against the same target in essentially the iden-
tical assay system, but utilizes a different mode of detection
(Thorne et al., 2010). For FLuc-based assays, reporters such
as RLuc, b-lactamase, or GFP can be used to test for reporter-
specific effects. An orthogonal assay is ideally performed in
advance of secondary assays to confirm that the activity of the
compound(s) is reporter independent. Secondary assays are
used to test the activity of the compounds found active in the
primary (and orthogonal) assay (Thorne et al., 2010). It has
been our experience that when more complex secondary assays
(e.g., qRT-PCR, immunohistochemistry, and western blots) are
used to define compound activity without first establishing
reporter-independent activity, a common outcome is inconclu-
sive or ambiguous results that may be misinterpreted.
Certain cell-based FLuc assays are more susceptible to FLuc
inhibitor-based reporter stabilization than others. These cell-
based assays tend to generate an initially low basal level of
FLuc protein and thus FLuc signal, and active compounds are
readily identified as those that cause an apparent increase in
FLuc activity, an effect that is augmented with longer-compound
incubation times. Therefore, if separate FLuc cell-based assays
are intended as a counter-screen to eliminate compounds that
may be FLuc inhibitors, it is important that the following variables
be similar between the two assays, because each can affect
apparent activation: basal level of luciferase signal, compound
exposure time, and detection protocol. One research group
developed a FLuc reporter with attenuated expression (e.g., an
SV40 promoter) to mimic low basal levels of FLuc for the purpose
of using the resulting data as a counter-screen (Lyssiotis et al.,
2009).
Given all the complexities inherent to FLuc, the question that
comes to mind is whether this enzymatic reporter is a good
choice for the design of cell-based assays aimed at compound
discovery efforts. It is our experience that the sensitivity inherent
to FLuc as a reporter is currently required for many assays, and
with its ease of use, it provides a robust assay design for use
with HTS. Additionally, it is important to note that the artifacts
associated with luciferases can be understood in relation to
the enzymology of the reporter, making their activity relatively
predictable. In contrast, artifacts associated with other assay
formats, like fluorescence, can be less predictable (Simeonov
et al., 2008). Further research and development of luciferases
that demonstrate improved resistance to small molecule inhibi-
tion and reporter stabilization would be valuable.
Conclusion
As described in this review, the interaction of small molecules
with luciferases can significantly interfere with HTS results.
Oftentimes, this interaction is not recognized by researchers
because of the insidious nature of the effect—for example,
apparent activation of luciferase by compounds that inhibit theChemistry & Bienzyme in cell-based assays. However, deceptive interactions
of small molecules with assay components are not limited to
the reporter FLuc. Recently, the activity of compounds thought
to enhance the affinity of the human deacetylase SIRT1 for an
acetylated p53 peptide (Howitz et al., 2003; Milne et al., 2007)
have been shown to be confounded by the fluorescent-tag on
the peptide used in the primary assays (Kaeberlein et al., 2005;
Pacholec et al., 2010). For these reasons, we are trying to imple-
ment the policy of confirming compound activity in orthogonal
assays—that is, an assay that uses a different reporter or assay
format—to establish reporter-independent activity prior to
experiments that inherently have more variables. Widespread
use of FLuc reporter assays in chemical biology arose from their
initial use as a reporter in molecular biology applications to
study, for example, regulation of gene expression. However,
adaptation of these reporter assays for HTS of large chemical
libraries creates an underappreciated complexity that must be
considered upon interpretation of results derived from these
assays—how compounds interact and affect reporter enzy-
mology and intracellular half-life. Studies aimed at acquiring
a better understanding of compound-reporter interactions, and
the factors that can subvert meaningful results, should help the
identification of improved leads for drug discovery and chemical
biology research.SUPPLEMENTAL INFORMATION
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